Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer

Oncology (Switzerland)

Volumn 53, Issue 2, 1996, Pages 104-111

  Lundin, J ^a   Nordling, S ^b   von Boguslawsky, K ^b   Roberts, P J ^a   Haglund, C ^a  

^a Fourth Department of Surgery   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Gene protein; p53; Pancreatic neoplasms; Tumor suppressor

Indexed keywords

CARMOFUR; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029917644     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227545     Document Type: Article

References (52)

1. Wingo PA, Long T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995:45:8-30.
2. Gudjonsson B: Cancer of the pancreas. 50 years of surgery. Cancer 1987:60:2284-2303.
3. Tredc M, Schwall G, Sacger HD: Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990:211:447-448.
4. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-124.
5. Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995:221:59-66.
6. Lemoine NR, Hall PA: Growth factors and oncogenes in pancreatic cancer. Bailleres Clin Gastroenterol 1990:4:815-832.
7. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 1989:49:4682-4689.
8. Shibata D, C'apella G, Pcrucho M: Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Baillieres Clin Gastroenterol 1990:4:151-169.
9. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988:53:549-554.
10. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993:9:138-141.
11. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Russel RC. Neoptolemos J. Williamson RC. Lane DP. Le-moinc NR: Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. BrJ Cancer 1991:64:1076-1082.
12. Ruggeri B, Zang SY, Caamano J, DiRado M, Flynn SD, Klein Szanto AJ: Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-I tumor-suppressor genes. Oncogene 1992:7:1503-1511.
13. Simon B, Weinel R, Hohne M, Watz J, Schmidt J, Kortner G, Arnold R: Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology 1994:106:1645-1651.
14. Harris CC: p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993:262:1980-1981.
15. Levine AJ, Montand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991:351: 453-456.
16. Hunter T: Braking the cycle. Cell 1993:75:839-841.
17. Svmonds H, Krall L, Remington L, Saenz Robles M, Lowe S, Jacks T, Van Dyke T: p53-dcpendcnt apoptosis suppresses tumor growth and progression in vivo. Cell 1994:78:703-711.
18. Harris CC, Hollstcin M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
19. Bartck J, Bartokova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV. Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991:6:1699-1703.
20. Dowell SP, Hall PA: The clinical relevance of the p53 tumour suppressor gene. Cytopatholo-gy 1994:5:144-145.
21. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C. Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993:142:1534-1543.
22. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992: 84:1109-1114.
23. Sarkis AS, Dalbagni G, Cordon Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW. Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993:85:53-59.
24. Lipponcn P, Ji H, Aaltomaa S, Syrjanen S, Syr-janen K: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993:55:51-56.
25. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, Cameron JL. Offerhaus GJ: Ovcrcxpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994:101:684-688.
26. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive. highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992:84:883-887.
27. Allred DC, Clark GM, Ellcdgc R, Fuqua SA, Brown RW, Chamncss GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
28. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN. Schwartz L. Chen LC. Mayall BH. Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992:84: 845-855.
29. Martin HM, Filipc ML, Morris RW, Lane DP. Silvestre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992:50:859-862.
30. Jovpaul BV, Hopwood D, Newman EL, Qurc-shi S, Grant A, Ogston SA, Lane DP. Cuschicri A: The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. BrJ Cancer 1994:69: 943-946.
31. Crook T, Vousdcn KH: Properlics of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992:11:3935-3940.
32. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Rcsnick JM, Fraley EE, Zhang G, Niehans GA: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994:86:1470-1475.
33. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschck T, Nordenskjold B: Prog-nost ic sign ificance of cytoplasmic p5 3 oncoprotein in colorectal adenocarcinoma. Lancet 1992:340:1369-1373.
34. Yantaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonentura Y, Miwa K, Miyazaki I: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992:70:2778-2784.
35. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M: Ovcrexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994:70:293-296.
36. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994:54:2496-2503.
37. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992:52:4828-4831.
38. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF. Quirke P: p53 in colorectal cancer: Clini-copathological correlation and prognostic significance. Br J Cancer 1991:63:317-319.
39. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC: The reialionsip of p53 immu-nostaining to survival in carcinoma of the lung. Br J Cancer 1992:66:735-738.
40. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Dcbruyne FM, Schalken JA: p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994:70: 496-500.
41. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M: p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994:14:2477-2484.
42. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, Namiki M, Klein Szanto AJ: Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994:118:150-154.
43. Vojtesek B, Bartck J, Midglcy CA, Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992:151: 237-244.
44. Baas IO, Mulder JW, Offerhaus GJ, Vogclstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994:172:5-12.
45. von Boguslawskv K: Immunohistochemical detection of progesterone receptors in paraffin sections. A novel method using microwave oven pretreatmcnt. APM1S 1994; 102:641-646.
46. Hsu SM, Raine L, Fanger H: Useofavidin-bio-tin peroxidase complex (ABC) in immunoper-oxidasc techniques: A comparison between ABC and unlabelcd antibody (PAP) procedures. J Histochcm Cytochem 1981:29:577-580.
47. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Beger HG, Korc M: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993:69:151-160.
48. Kalthoff H, Schmiegel W, Rocder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantcl K, Ricthmullcr G. et al: p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993:8:289-298.
49. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rcjthar A, Kovarik J, Millis RR, Lane DP, Barnes DM: Immunochemical analysis of the 53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993:6: 881-886.
50. Levine MN, Brownman GP, Gent M, Roberts R, Goodyear M: When is a prognostic factor useful'.’ A guide for the perplexed. J Clin Oncol 1991;9:348-356.
51. Suzuki T, Takano Y: Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas. Jpn J Cancer Res 1993:84: 1072-1077.
52. Hollstcin M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991:253:49-53.